NuCana's Former CFO Joins Aurion Biotech to Drive Growth in Regenerative Medicine

Leadership Changes Signal New Directions for Aurion Biotech

Aurion Biotech, Inc. announces the strategic appointment of Donald Munoz as its new chief financial officer (CFO), a move that may significantly influence the company's growth trajectory in the regenerative medicine sector. Munoz, who brings over 30 years of healthcare experience, including a notable tenure as CFO at NuCana plc, is expected to leverage his financial acumen to bolster Aurion's ambitious plans. His previous role at NuCana involved navigating complex financial operations and spearheading substantial fundraising initiatives, such as a $114 million initial public offering and an $80 million follow-on offering. His track record positions him as a valuable asset to Aurion, particularly as the company seeks to capitalize on its innovative therapies.

Munoz's extensive background in healthcare investment banking complements his financial leadership experience. Having completed over 100 financing and strategic advisory transactions, he possesses a deep understanding of the financial landscape within the biotech industry. His enthusiasm for Aurion’s lead product candidate, AURN001, underscores his commitment to the company's mission. AURN001 is designed to treat corneal endothelial disease, a condition that can result in blindness, and Munoz's financial expertise could be instrumental in advancing this promising therapy through the clinical stages and into market readiness.

Aurion Biotech is currently riding a wave of positive momentum, highlighted by recent successful outcomes from its CLARA Phase 1/2 clinical trial, which demonstrated encouraging six-month top-line results in the U.S. and Canada. The company's commitment to pioneering regenerative therapies is further evidenced by its recognition with the Prix Galien award for best startup in biotech in 2022 and the launch of the first commercially available corneal endothelial cell therapy in Japan. With Munoz at the financial helm, Aurion looks poised to drive forward its vision of restoring sight through innovative treatments.

In addition to Munoz's appointment, Aurion's strategic focus on developing AURN001 aligns with the growing emphasis on regenerative medicine in addressing unmet medical needs. The company's dedication to innovative therapies positions it as a key player in the competitive biotech landscape. As Aurion continues to advance its pipeline, stakeholders eagerly anticipate how Munoz's leadership will shape the company's financial strategies and operational growth.

For further details on Aurion's advancements and initiatives, interested parties can visit their website at www.aurionbiotech.com.